{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:27:00Z","timestamp":1784251620903,"version":"3.55.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its third edition of the Global Multi-Stakeholders\u2019 Summit, gathering key primary immunodeficiencies (PID) stakeholders and experts to discuss and foment global collaboration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This edition focused on the impact of genomic medicine in PID treatment, the role of digital health, including artificial intelligence, in PID care, and how to anticipate and minimise risks to ensure optimal patient access to care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>These discussions aimed to examine current hurdles and brainstorm feasible solutions and priorities for the PID community in these areas in the next ten years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These discussions led to recommendations for comprehensive approaches to care and access to treatment for PID patients, suggesting actions that will bring the community closer to treatments based on real-world evidence and adjusted to patient\u2019s needs. To accomplish this, collaboration between academia, industry, regulatory authorities, and patients is crucial.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1596971","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:29:24Z","timestamp":1750138164000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years"],"prefix":"10.3389","volume":"16","author":[{"given":"L\u00facia","family":"Mamede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser Cantenys","family":"Sab\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samya","family":"Van Coillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Pre\u0301vot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sa\u0301nchez-Ramo\u0301n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Barasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn W.","family":"Schuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal","family":"Hendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Garcelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi D.","family":"Notarangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Drabwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J. T.","family":"Staal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan O.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Van Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Pergent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques G.","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Mahlaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.12.790","article-title":"An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years","volume":"149","author":"Alligon","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1430678","article-title":"Charting a course for global progress in PIDs by 2030 \u2014 proceedings from the IPOPI global multi-stakeholders\u2019 summit (September 2023)","volume":"15","author":"Van Coillie","year":"2024","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1245718","article-title":"The PID Odyssey 2030: outlooks, unmet needs, hurdles, and opportunities \u2014 proceedings from the IPOPI global multi-stakeholders\u2019 summit (June 2022)","volume":"14","author":"Tadros","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00056-w","article-title":"FDA approves gene therapy for metachromatic leukodystrophy, the tenth for a genetic disease and the priciest yet","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0020-9","article-title":"Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges","volume":"18","author":"Cavazzana","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.omtm.2017.10.001","article-title":"Interactions between retroviruses and the host cell genome","volume":"8","author":"Poletti","year":"2018","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-02765-9","article-title":"Pioneers of revolutionary CRISPR gene editing win chemistry Nobel","volume":"586","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B2100009","article-title":"CRISPR\/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement","volume":"22","author":"Li","year":"2021","journal-title":"J Zhejiang Univ-Sci B"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2021.618346","article-title":"The promise and the hope of gene therapy","volume":"3","author":"Papanikolaou","year":"2021","journal-title":"Front Genome Ed"},{"key":"B18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1001\/jamapediatrics.2024.1116","article-title":"Evolution of gene therapy for inborn errors of immunity","volume":"178","author":"Somekh","year":"2024","journal-title":"JAMA Pediatr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000952","article-title":"Advances in gene therapy for inborn errors of immunity","volume":"23","author":"Ott de Bruin","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5235.470","article-title":"Gene therapy in peripheral blood lymphocytes and bone marrow for ADA\u2013 immunodeficient patients","volume":"270","author":"Bordignon","year":"1995","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2022.899294","article-title":"Gene edited T cell therapies for inborn errors of immunity","volume":"4","author":"Fox","year":"2022","journal-title":"Front Genome Ed"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-00809-y","article-title":"Cutting-edge CAR-T cancer therapy is now made in India \u2014 at one-tenth the cost","volume":"627","author":"Mallapaty","year":"2024","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0676-z","article-title":"Benefit Corporation: a path to affordable gene therapies","volume":"25","author":"Fischer","year":"2019","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"dmm050623","DOI":"10.1242\/dmm.050623","article-title":"Improving access to gene therapy for rare diseases","volume":"17","author":"Fox","year":"2024","journal-title":"Dis Model Mech"},{"key":"B27","unstructured":"Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform\n          \n          \n          2022"},{"key":"B28","unstructured":"Bluebird, winding down in Europe, withdraws another rare disease gene therapy"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01934-9","article-title":"Ensuring a future for gene therapy for rare diseases","volume":"28","author":"Aiuti","year":"2022","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.01.003","article-title":"Chimeric antigen receptor\u2013T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods","volume":"21","author":"Harrison","year":"2019","journal-title":"Cytotherapy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/hae.v28.S2","article-title":"Alternative payment models for durable and potentially curative therapies: The case of gene therapy for haemophilia A","volume":"28","author":"Goodman","year":"2022","journal-title":"Haemophilia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2217\/rme-2020-0169","article-title":"The use of innovative payment mechanisms for gene therapies in europe and the USA","volume":"16","author":"J\u00f8rgensen","year":"2021","journal-title":"Regener Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/d43978-023-00145-1","article-title":"Rescue of an orphan drug points to a new model for therapies for rare diseases","author":"Valsecchi","year":"2023","journal-title":"Nat Italy"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a novel anti-CD19 chimeric antigen receptor: A paradigm for an affordable CAR T cell production at academic institutions","volume":"12","author":"Castella","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01463-y","article-title":"The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001","volume":"57","author":"Trias","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00627","article-title":"Primary immune deficiencies - principles of care","volume":"5","author":"Chapel","year":"2014","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13023-021-02161-0","article-title":"The PID Life Index: an interactive tool to measure the status of the PID healthcare environment in any given country","volume":"17","author":"Sol\u00eds","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1151335","article-title":"Primary immunodeficiencies (PID) Life Index in Southeast Asia: A comparative analysis of PID Principles of Care (PoC)","volume":"14","author":"Chan","year":"2023","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02208-8","article-title":"Access to gene therapy for rare diseases when commercialization is not fit for purpose","volume":"29","author":"Fox","year":"2023","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/frai.2023.1227091","article-title":"Artificial intelligence in clinical medicine: catalyzing a sustainable global healthcare paradigm","volume":"6","author":"Krishnan","year":"2023","journal-title":"Front Artif Intell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s44163-023-00049-5","article-title":"Evaluation of artificial intelligence techniques in disease diagnosis and prediction","volume":"3","author":"Ghaffar Nia","year":"2023","journal-title":"Discov Artif Intell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1109\/JSTSP.2017.2764438","article-title":"End-to-end multimodal emotion recognition using deep neural networks","volume":"11","author":"Tzirakis","year":"2017","journal-title":"IEEE J Sel Top Signal Process"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1109\/TPAMI.2023.3325770","article-title":"COLD fusion: calibrated and ordinal latent distribution fusion for uncertainty-aware multimodal emotion recognition","volume":"46","author":"Tellamekala","year":"2024","journal-title":"IEEE Trans Pattern Anal Mach Intell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3390\/bioengineering10121435","article-title":"How artificial intelligence is shaping medical imaging technology: A survey of innovations and applications","volume":"10","author":"Pinto-Coelho","year":"2023","journal-title":"Bioengineering"},{"key":"B45","article-title":"Identification of similar patients through medical concept embedding from electronic health records: A feasibility study for rare disease diagnosis","volume-title":"Studies in Health Technology and Informatics","author":"Chen","year":"2021"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.786710","article-title":"Patient-patient similarity-based screening of a clinical data warehouse to support ciliopathy diagnosis","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"B47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-981-15-4095-0_2","article-title":"Introduction to reinforcement learning","volume-title":"Deep Reinforcement Learning","author":"Ding","year":"2020"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/sim.v41.20","article-title":"Deep reinforcement learning for personalized treatment recommendation","volume":"41","author":"Liu","year":"2022","journal-title":"Stat Med"},{"key":"B49","first-page":"1044 p","volume-title":"Speech and language processing: an introduction to natural language processing, computational linguistics, and speech recognition","author":"Jurafsky","year":"2024"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocw144","article-title":"Improving a full-text search engine: the importance of negation detection and family history context to identify cases in a biomedical data warehouse","volume":"24","author":"Garcelon","year":"2017","journal-title":"J Am Med Inform Assoc"},{"key":"B51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13023-018-0830-6","article-title":"Next generation phenotyping using narrative reports in a rare disease clinical data warehouse","volume":"13","author":"Garcelon","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B52","article-title":"Using deep learning to improve phenotyping from clinical reports","volume-title":"Studies in Health Technology and Informatics","author":"Vincent","year":"2022"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100224","DOI":"10.1016\/j.jacig.2024.100224","article-title":"Natural language processing of clinical notes enables early inborn error of immunity risk ascertainment","volume":"3","author":"Roberts","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2020.03.005","article-title":"Evaluation of the frequency and diagnostic delay of primary immunodeficiency disorders among suspected patients based on the 10 warning sign criteria: A cross-sectional study in Iran","volume":"48","author":"Bahrami","year":"2020","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.01.002","article-title":"Proceedings from the inaugural Artificial Intelligence in Primary Immune Deficiencies (AIPID) conference","volume":"153","author":"Rivi\u00e8re","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46860","article-title":"The impact of artificial intelligence on optimizing diagnosis and treatment plans for rare genetic disorders","volume":"15","author":"Abdallah","year":"2023","journal-title":"Cureus"},{"key":"B57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13223-023-00790-7","article-title":"Development of a primary care screening algorithm for the early detection of patients at risk of primary antibody deficiency","volume":"19","author":"Messelink","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.10.005","article-title":"A validated artificial intelligence-based pipeline for population-wide primary immunodeficiency screening","volume":"151","author":"Rider","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237285","article-title":"PI Prob: A risk prediction and clinical guidance system for evaluating patients with recurrent infections","volume":"16","author":"Rider","year":"2021","journal-title":"PloS One"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade4510","article-title":"Electronic health record signatures identify undiagnosed patients with common variable immunodeficiency disease","volume":"16","author":"Johnson","year":"2024","journal-title":"Sci Transl Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/cts.v16.11","article-title":"Artificial intelligence in rare disease diagnosis and treatment","volume":"16","author":"Wojtara","year":"2023","journal-title":"Clin Transl Sci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","article-title":"Artificial intelligence in drug discovery and development","volume":"26","author":"Paul","year":"2021","journal-title":"Drug Discov Today"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2196\/58933","article-title":"A 25-year retrospective of health IT infrastructure building: the example of the catalonia region","volume":"26","author":"Piera-Jim\u00e9nez","year":"2024","journal-title":"J Med Internet Res"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-56103-5","volume-title":"Handbook Integrated Care","author":"Amelung","year":"2017"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/3490234","article-title":"The secondary use of electronic health records for data mining: data characteristics and challenges","volume":"55","author":"Sarwar","year":"2023","journal-title":"ACM Comput Surv"},{"key":"B66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12911-023-02115-5","article-title":"Interoperability of heterogeneous health information systems: a systematic literature review","volume":"23","author":"Torab-Miandoab","year":"2023","journal-title":"BMC Med Inform Decis Mak"},{"key":"B67","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12911-024-02458-7","article-title":"Conceptual design of a generic data harmonization process for OMOP common data model","volume":"24","author":"Henke","year":"2024","journal-title":"BMC Med Inform Decis Mak"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1701984","article-title":"Patient identification techniques \u2013 approaches, implications, and findings","volume":"29","author":"Riplinger","year":"2020","journal-title":"Yearb Med Inform"},{"key":"B69","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00778-022-00775-9","article-title":"Data collection and quality challenges in deep learning: a data-centric AI perspective","volume":"32","author":"Whang","year":"2023","journal-title":"VLDB J"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1109\/JBHI.2024.3406737","article-title":"A review of AIoT-based human activity recognition: from application to technique","volume":"29","author":"Qi","year":"2024","journal-title":"IEEE J BioMed Health Inform"},{"key":"B71","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2018.8374","article-title":"Health data and privacy in the digital era","volume":"320","author":"Gostin","year":"2018","journal-title":"JAMA"},{"key":"B72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10875-024-01825-3","article-title":"Development of an expert-based scoring system for early identification of patients with inborn errors of immunity in primary care settings \u2013 the PIDCAP project","volume":"45","author":"Rivi\u00e8re","year":"2025","journal-title":"J Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jbi.2018.02.019","article-title":"A clinician friendly data warehouse oriented toward narrative reports: Dr. Warehouse","volume":"80","author":"Garcelon","year":"2018","journal-title":"J BioMed Inform"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.01.011","article-title":"Validating inborn error of immunity prevalence and risk with nationally representative electronic health record data","volume":"153","author":"Rider","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B75","volume-title":"Medical Product Alert N\u00b03\/2022: Falsified Intratect (Human normal immunoglobulin)","year":"2022"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/vox.v119.9","article-title":"Immunoglobulin solutions for patients with primary immunodeficiency. Comments on Burnouf et\u00a0al.\u2019s \u2018Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low- and middle-income countries.\u2019","volume":"119","author":"Pergent","year":"2024","journal-title":"Vox Sang"},{"key":"B77","doi-asserted-by":"publisher","first-page":"102758","DOI":"10.1016\/j.tmaid.2024.102758","article-title":"Global perspective of the risks of falsified and counterfeit medicines: A critical review of the literature","volume":"61","author":"Feeney","year":"2024","journal-title":"Travel Med Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250003","article-title":"Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"1","author":"Poli","year":"2025","journal-title":"J Hum Immun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01551-2","article-title":"An international survey of allogeneic hematopoietic cell transplantation for X-linked agammaglobulinemia","volume":"43","author":"Nishimura","year":"2023","journal-title":"J Clin Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.771966","article-title":"Critical reflections on reimbursement and access of advanced therapies","volume":"13","author":"Simoens","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1596971\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:29:27Z","timestamp":1750138167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1596971\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2025.1596971"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1596971","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"article-number":"1596971"}}